Differential expression of mTOR signalling components in drug resistance in ovarian cancer

Anticancer Research

Volumn 30, Issue 9, 2010, Pages 3529-3534

  Foster, Helen ^a   Coley, Helen M ^b   Goumenou, Anastasia ^c   Pados, George ^d   Harvey, Amanda ^a   Karteris, Emmanouil ^a  

^a BRUNEL UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

DEPTOR; mTOR; Ovarian cancer; Paclitaxel resistance; S6 kinase

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PROTEIN DEPTOR; PROTEIN P70; PROTEIN RAPTOR; PROTEIN RICTOR; S6 KINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; MTOR PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CANCER CELL CULTURE; DOWN REGULATION; DRUG RESISTANCE; IMMUNOFLUORESCENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; DRUG EFFECTS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; OVARY TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; OVARIAN NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 77958524854     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. De Cecco L, Marchionni L, Gariboldi M, Reid JF, Lagonigro MS, Caramuta S, Ferrario C, Bussani E, Mezzanzanica D, Turatti F, Delia D, Daidone MG, Oggionni M, Bertuletti N, Ditto A, Raspagliesi F, Pilotti S, Pierotti MA, Canevari S and Schneider C: Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene 23: 8171-8183, 2004. (Pubitemid 39531858)
2. Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J and Ramon y Cajal S: Phosphorylated 4E binding protein 1 : a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 107: 1801-1811, 2006.
3. Hay N and Sonenberg N: Upstream and downstream of mTOR. Genes Dev 18: 1926-1945, 2004.
4. Yap TA, Carden CP and Kaye SB: Beyond chemotherapy: targeted therapies in ovarian cancer. Nature Rev Cancer 9: 167-181, 2009.
5. Agarwal R and Kaye SB: Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nature Rev Cancer 5: 502-516, 2003. (Pubitemid 37328838)
6. Orr GA, Verdier-Pinard P, McDaid H and Horwitz SB: Mechanisms of Taxol resistance related to microtubules. Oncogene 22: 7280-7295, 2003.
7. Blagosklonny MV and Fojo T: Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 83: 151-156, 1999.
8. Dumontet C and Sikic BI: Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17: 1061-1070, 1999.
9. Drukman S and Kavallaris M: Microtubule alterations and resistance to tubulin-binding agents. Int J Oncol 21: 621-628, 2002.
10. Coley HM: Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 34: 378-390, 2008.
11. Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, Hensley HH, Hamilton TC and Testa JR: RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 67: 2408-2413, 2007.
12. Faried LS, Faried A, Kanuma T, Nakazato T, Tamura T, Kuwano H and Minegishi T: Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel. Eur J Cancer 42: 934-947, 2006.
13. Kim SH, Juhnn YS and Song YS: Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann NY Acad Sci 1095: 82-89, 2007. (Pubitemid 47092440)
14. Bjornsti MA and Houghton PJ: The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4: 335-348, 2004.
15. Dutcher JP: Mammalian target of rapamycin inhibition. Clin Cancer Res 10: 6382-7S, 2004.
16. Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK and Testa JR: AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 5: 853-857, 2004.
17. Meng Q, Xia C, Fang J, Rojanasakul Y and Jiang BH: Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal 18: 2262-2271, 2006. (Pubitemid 44636166)
18. Huang S and Houghton PJ: Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs 3: 295-304, 2002.
19. Aissat N, Le Tourneau C, Ghoul A, Serova M, Bieche I, Lokiec F, Raymond E and Faivre S: Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 62: 305-313, 2008.
20. Ma XY, Wang SX, Liu Y, Liu RH, Lu YP and Ma D: Induction effect of rapamycin combined paclitaxel on apoptosis of ovarian cancer cell lines A2780 and SKOV3 and the molecular mechanism. Ai Zheng 26: 367-370, 2007.
21. Kurmasheva RT, Huang S and Houghton PJ: Predicted mechanisms of resistance to mTOR inhibitors Br J Cancer 95: 955-960, 2006.
22. Treeck O, Wackwitz B, Haus U and Ortmann O: Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol 102: 292-299, 2006.
23. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS and Sabatini DM: DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137: 873-886, 2009.
24. Liu Y, Hidayat S, Su WH, Deng X, Yu DH and Yu BZ: Expression and activity of mTOR and its substrates in different cell cycle phases and in oral squamous cell carcinomas of different malignant grade. Cell Biochem Funct 25: 45-53, 2007. (Pubitemid 46121783)
25. Lauten M, Fernandez-Munoz I, Gerdes K, von Neuhoff N, Weite K, Schlegelberger B, Schrappe M and Beger C: Kinetics of the in vivo expression of glucocorticoid receptor splice variants during prednisone treatment in childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer 2: 459-463, 2009.
26. Karteris E, Grammatopoulos D, Randeva H and Hillhouse EW: Signal transduction characteristics of the corticotropin-releasing hormone receptors in the feto-placental unit. J Clin Endocrinol Metab 85: 1989-1996, 2000.
27. Coley HM, Shotton CF, Ajose-Adeogun A, Modjtahedi H, Thomas H: Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. Biochem Pharmacol 72: 941-948, 2006.
28. Roos S, Jansson N, Palmberg I, Säljö K, Powell TL and Jansson T: Mammalian target of rapamycin in the human placenta regulates leucine transport and is down-regulated in restricted fetal growth. J Physiol 582: 449-459, 2007.
29. Bachmann RA, Kim JH, Wu AL, Park IH and Chen J: A nuclear transport signal in mammalian target of rapamycin is critical for its cytoplasmic signaling to S6 kinase 1. J Biol Chem 281: 7357-7363, 2006.
30. Saitoh M, Pullen N, Brenman P, Centrell D and Dennis PB: Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site. J Biol Chem 277: 20104-20202, 2002.